Cancer Biomarkers Market Size, Growth and Forecast 2032

Cancer Biomarkers Market Overview:

The global Cancer Biomarkers Market size was estimated at USD 38349 million in 2025 and is expected to reach USD 87462.46 million by 2032, growing at a CAGR of 12.5% from 2025 to 2032. Growth is primarily driven by the accelerating clinical shift toward biomarker-guided oncology, where test results directly inform screening decisions, therapy selection, and longitudinal monitoring across major tumor types. The expansion of multi-omics profiling, wider adoption of blood-based testing formats, and stronger integration of companion diagnostics into routine care pathways continue to broaden test menus and increase per-patient testing intensity across mature and emerging healthcare systems.

Key Market Trends & Insights

• The Cancer Biomarkers Market is projected to expand at a CAGR of 5% (2025–2032), reflecting rapid scaling of precision oncology testing volumes.
• Breast Cancer accounted for the largest share of 34.4% in 2025, supported by high screening intensity and guideline-aligned biomarker utilization.
• Protein / Proteomic Biomarkers held 50.9% share in 2025, sustained by entrenched clinical workflows and broad assay availability.
• Hospitals & Specialty Clinics captured 40.3% share in 2025, driven by integrated diagnostic-to-treatment decision cycles and turnaround-time priorities.
• North America represented 39.8% share in 2025, supported by reimbursement depth, advanced laboratory infrastructure, and high adoption of molecular profiling.

Segment Analysis

Cancer biomarker adoption is advancing as oncology care moves toward earlier risk identification and more frequent monitoring across the treatment journey. Blood-based testing formats are improving ordering convenience and enabling broader screening and surveillance use cases, particularly when paired with scalable laboratory workflows. Multi-omics platforms are increasing discovery throughput and expanding clinically actionable panels beyond single-marker assays, strengthening demand for integrated testing menus.

Companion diagnostics and therapy-selection use cases remain central to clinical uptake as targeted regimens expand across breast, lung, colorectal, and prostate cancers. Bioinformatics and AI-driven interpretation are improving clinical actionability for complex profiles, supporting adoption of larger panels in routine practice. Outsourcing to high-throughput reference laboratories is expanding, but hospitals and specialty clinics continue to anchor decision-making where rapid turnaround and care integration are critical.

By Cancer Type Insights

Breast Cancer accounted for the largest share of 34.4% in 2025. High screening intensity, established care pathways, and frequent biomarker-driven treatment decisions support sustained testing volume in breast oncology. Strong linkage to companion diagnostics for targeted and endocrine therapies increases repeat testing and encourages broader panels. Longitudinal monitoring and recurrence risk stratification further raise testing frequency across clinical settings.

By Biomarker Type Insights

Protein / Proteomic Biomarkers accounted for the largest share of 50.9% in 2025. Protein-marker assays remain deeply embedded in routine oncology workflows and are widely accessible across hospital and reference laboratory platforms. Standardized test performance and mature clinical evidence support continued demand for protein-based markers in diagnosis, prognosis, and therapy monitoring. At the same time, expanding multi-analyte approaches increasingly complement protein markers with genomic and epigenomic signals.

By Application Insights

Diagnostics remains the primary commercialization route for cancer biomarkers, spanning screening support, diagnosis confirmation, prognosis, and treatment selection. Clinical demand is strengthened by guideline-driven testing and the need for rapid, actionable results at key decision points. Drug discovery and development continues to adopt biomarkers to stratify patients, enrich responder populations, and shorten development cycles. Personalized medicine use expands as profiling results increasingly direct targeted regimens and longitudinal monitoring strategies.

By End User Insights

Hospitals & Specialty Clinics accounted for the largest share of 40.3% in 2025. Hospital-led oncology pathways prioritize rapid turnaround for therapy selection, driving in-house testing growth and tight integration with clinical workflows. Specialty clinics contribute through structured treatment pathways that rely on biomarker results for regimen optimization and monitoring. Reference laboratories scale high-throughput sequencing and analytics, strengthening outsourced testing volumes, but hospital-centered decision cycles preserve strong demand within care delivery networks.

By Technology Insights

OMICS Technologies accounted for the largest share of 33.1% in 2025. Omics platforms benefit from high-throughput profiling capabilities and expanding use in both tumor tissue profiling and liquid biopsy workflows. Declining sequencing costs, improved automation, and standardized pipelines support broader adoption across clinical laboratories. Imaging-linked biomarker development is progressing through digital pathology and AI enablement, but omics remains central to comprehensive molecular characterization.

Cancer Biomarkers Market Drivers

Expansion of Precision Oncology and Companion Diagnostics

Precision oncology adoption is increasing the clinical reliance on validated biomarkers for therapy selection and monitoring. Oncology workflows increasingly require biomarker confirmation before initiating targeted regimens, raising testing volume per patient episode. Companion diagnostics integration also broadens the addressable testing menu across tumor types and treatment classes. Broader panel usage is encouraged by clinical guidelines and the need for comprehensive molecular characterization at diagnosis and progression.

• For instance, Foundation Medicine's FoundationOne CDx reached a cumulative milestone of 100 approved companion diagnostic indications across the United States and Japan by late 2025, comprising 57 U.S. FDA approvals and 43 approvals from Japan's Ministry of Health, Labour, and Welfare all delivered through a single NGS-based platform covering 324 cancer-associated genes across solid tumor types.

Growth in Liquid Biopsy and Blood-Based Testing Adoption

Liquid biopsy adoption is expanding due to convenience, repeatability, and the ability to support longitudinal monitoring. Blood-based formats reduce barriers compared with invasive tissue sampling and enable earlier detection and surveillance use cases. Expanded utilization increases test frequency across screening, treatment response tracking, and recurrence monitoring. Laboratory standardization and improved assay sensitivity continue to strengthen clinical confidence and support wider adoption across hospitals and reference laboratories.

• For instance, GRAIL's Galleri multi-cancer early detection (MCED) test was evaluated across a real-world cohort of 111,080 individuals, demonstrating an empirical positive predictive value of 49.4% and a cancer signal origin localization accuracy of 87% figures consistent with its controlled clinical validation performance.

Rising Oncology Burden and Screening Program Intensification

Growing cancer incidence and expanding screening programs increase demand for early detection and risk stratification tools. Biomarker testing supports earlier clinical action and improves treatment pathway selection, reinforcing use across major tumor types. Health systems increasingly prioritize diagnostic efficiency to reduce late-stage treatment intensity and improve outcomes. These factors support sustained demand growth across both established and emerging markets.

Advancements in Multi-Omics Platforms and Bioinformatics

High-throughput sequencing, proteomics, and integrated analytics are accelerating biomarker discovery and clinical translation. Bioinformatics improvements enhance interpretation of complex profiles, supporting clinical actionability and broader panel deployment. Workflow automation is improving scalability and repeatability, supporting higher testing throughput in routine practice. Continued platform innovation expands clinical utility across diagnostics, monitoring, and personalized medicine use cases.

Cancer Biomarkers Market Challenges

Cancer biomarker commercialization faces variability in clinical validation requirements, assay standardization, and real-world evidence expectations across jurisdictions. Laboratory-to-laboratory differences in sample handling, platform selection, and interpretation pipelines can reduce comparability and slow broader adoption. Reimbursement fragmentation and coverage uncertainty can limit uptake, particularly for newer multi-analyte tests and expanded screening applications. These factors can lengthen time-to-scale despite strong clinical interest.

Operational constraints remain significant as high-complexity testing requires skilled personnel, robust quality systems, and reliable supply chains for reagents and consumables. Data interpretation burdens increase with multi-omics profiling, raising dependence on specialized informatics and clinician education. Integration into clinical workflows can be uneven when ordering pathways, turnaround times, and reporting formats are not optimized. Cost sensitivity across emerging markets can further constrain broad access to advanced testing.

• For instance, Caris Life Sciences states that its MI Profile/MI Cancer Seek workflow combines whole exome and whole transcriptome sequencing across 23,000+ genes with protein analysis and AI-predictive algorithms, while the FDA-approved MI Cancer Seek reports SNVs and indels in 228 genes plus MSI, TMB, and one copy-number amplification marker, underscoring the informatics and operational depth required for routine deployment.

Cancer Biomarkers Market Trends and Opportunities

Multi-cancer early detection and broader blood-based screening strategies are creating new commercialization pathways beyond single-cancer assays. Expanded adoption is supported by improving test sensitivity, strong patient preference for minimally invasive options, and the ability to integrate ordering into routine care. As evidence accumulates, these modalities can expand addressable volume and support recurring testing models in screening and surveillance. The trend also creates opportunities for differentiated analytics and population-scale lab operations.

Technology convergence across omics platforms, digital pathology, and AI-enabled interpretation is strengthening clinical utility and improving workflow efficiency. Integrated reporting and decision-support tools can enhance clinician confidence and increase adoption within hospital systems. Partnerships between diagnostics firms, pharma, and health systems are expanding test availability and supporting companion diagnostic expansion. Growth opportunities also emerge from scaling reference laboratory networks and improving access in Asia Pacific and selected Middle East markets.

• For instance, Paige the first company to receive FDA authorization for an AI product in digital pathology demonstrated in its pivotal clinical study that pathologists using Paige Prostate Detect increased cancer detection sensitivity from 88.7% to 96.6%, achieved a 70% reduction in false-negative diagnoses, and a 24% reduction in false-positive diagnoses, with non-specialist pathologists reaching diagnostic accuracy on par with prostate specialists.

Regional Insights

North America (39.8%)

North America leads with a 39.8% share in 2025, supported by deep molecular diagnostics penetration, strong reimbursement coverage, and high routine adoption of precision oncology. Large reference labs and integrated health systems enable standardized workflows and high-throughput testing. Demand is reinforced by companion diagnostics and expanding blood-based formats for monitoring and screening-adjacent use cases, while continuous platform innovation and robust oncology pipelines sustain volumes.

Europe (24.9%)

Europe accounted for 24.9% share in 2025, backed by established oncology care pathways and increasing alignment of biomarker testing with clinical guidelines. Cross-border research networks and translational programs drive demand for validated, reproducible assays. Centralized testing hubs and expanding multi-omics capabilities in key markets support steady growth, with further upside tied to workflow standardization and broader access to advanced profiling.

Asia Pacific (23.6%)

Asia Pacific held 23.6% share in 2025, reflecting rapid expansion as oncology infrastructure and laboratory capacity scale across large populations. Adoption of sequencing and multi-omics workflows is rising due to precision medicine investments and growing cancer center networks. Outsourcing growth and larger diagnostic service providers improve access to advanced testing, while affordability gains and stronger clinical pathway integration support continued momentum.

Latin America (7.7%)

Latin America represented 7.7% share in 2025, with demand increasing as private lab networks and leading urban cancer centers expand molecular diagnostics capability. Access remains uneven due to reimbursement variability and concentration of advanced testing in higher-income segments. Growth opportunities include expanding regional reference labs, improving clinician education, and increasing availability of standardized panels through stronger hospital and oncology network partnerships.

Middle East & Africa (4.0%)

Middle East & Africa accounted for 4.0% share in 2025, growing from a smaller base with adoption concentrated in GCC markets, South Africa, and select hubs. Expanding oncology services and investment in diagnostics support gradual uptake of molecular profiling. Infrastructure gaps and variable reimbursement remain constraints, while centralized testing models and public–private partnerships can improve access to validated assays.

Competitive Landscape

The competitive landscape is shaped by breadth of biomarker testing menus, scalability of laboratory workflows, and the ability to deliver clinically actionable interpretation for complex profiles. Companies differentiate through validated assays, strong instrument and reagent ecosystems, and partnerships that embed tests into clinical pathways and drug development programs. Competitive intensity is rising in blood-based screening and multi-omics profiling, where performance, turnaround time, and evidence depth influence adoption across hospitals and reference laboratories.

1. Hoffmann-La Roche Ltd. emphasizes companion diagnostics and integrated oncology workflows by aligning assay development with therapeutic decision-making needs and standardized pathology systems. The company’s approach centers on broad clinical adoption through validated assays, platform integration, and support for routine testing in oncology care settings. Continued expansion of diagnostic portfolios and workflow enablement strengthens positioning in biomarker-guided treatment selection.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• F. Hoffmann-La Roche Ltd.
• Abbott
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Illumina, Inc.
• Agilent Technologies
• Bio-Rad Laboratories
• Hologic, Inc.
• Merck & Co.
• Becton, Dickinson and Company
• Exact Sciences
• Siemens Healthineers
• Guardant Health
• Foundation Medicine

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Recent Developments

• In September 2025, Illumina announced strategic partnerships with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on its TruSight™ Oncology (TSO) Comprehensive genomic profiling test.
• In May 2025, Thermo Fisher Scientific showcased a decade of pharma partnership in next-generation sequencing (NGS) companion diagnostics development and commercialization at the ASCO 2025 Annual Meeting, highlighting how its integrated solutions span from biomarker discovery through clinical commercialization.
• In April 2025, Agilent Technologies showcased innovative products and strategic partnerships focused on transforming cancer research, diagnostics, and therapeutics at the AACR Annual Meeting. The company highlighted its commitment to delivering comprehensive multiomic insights and cutting-edge diagnostic tools that empower researchers and clinicians to make more informed treatment decisions.
• In April 2025, QIAGEN announced a series of new products and partnership updates designed to strengthen its cancer genomic profiling portfolio, showcased at the American Association for Cancer Research (AACR) Annual Meeting in Chicago. The company launched new QIAseq panels providing deeper and more accurate insights into cancer biology and biomarker discovery, integrated with QIAGEN Digital Insights for genomic data analysis and interpretation.

Report Scope

Segmentation

By Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Other Cancer Types

By Biomarker Type

• Genetic Biomarkers
• Epigenetic Biomarkers
• Proteomic Biomarkers
• Metabolic Biomarkers
• Other Biomarker Types

By Application

• Diagnostics
• Drug Discovery & Development
• Personalized Medicine
• Other Applications

By End User

• Pharmaceutical & Biotechnology Companies
• Diagnostics & Research Laboratories
• Hospitals & Specialty Clinics
• Other End Users

By Technology

• OMICS Technologies
• Imaging Technologies
• Other Technologies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Expansion of Precision Oncology and Companion Diagnostics

The increasing adoption of precision oncology is driving demand for validated cancer biomarkers, as therapy selection and monitoring now often require biomarker confirmation. Integration of companion diagnostics into clinical pathways broadens the testing menu and increases per-patient testing frequency across multiple tumor types.

Growth in Liquid Biopsy and Blood-Based Testing Adoption

Blood-based and liquid biopsy formats are gaining traction due to their convenience, repeatability, and ability to support longitudinal monitoring. These minimally invasive tests enable earlier detection and more frequent surveillance, expanding the addressable market and increasing test volumes.

Rising Oncology Burden and Screening Program Intensification

The global rise in cancer incidence and the expansion of screening programs are fueling demand for early detection and risk stratification tools. Biomarker testing is increasingly used to guide earlier clinical intervention and optimize treatment pathways, supporting sustained market growth.

Advancements in Multi-Omics Platforms and Bioinformatics

Innovations in high-throughput sequencing, proteomics, and integrated analytics are accelerating biomarker discovery and clinical translation. Improved bioinformatics and automation enhance the scalability and clinical actionability of complex biomarker panels, driving broader adoption in routine oncology care.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.